Xspray Pharma Q4 2023: NDA-resubmission accepted by the FDA
Research Update
2024-02-16
08:37
Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently announced PDUFA-date at the end of July marks a significant catalyst for the stock.
FE
Filip Einarsson
Analyst Q&A
Closed
Filip Einarsson answered 7 questions.
Disclosures and disclaimers